Skip to main content
Top
Published in: Journal of General Internal Medicine 6/2015

01-06-2015 | Clinical Practice: Exercises in Clinical Reasoning

Exercises In Clinical Reasoning

A Confusing Interaction

Authors: Urvi A. Shah, MD, Mark C. Henderson, MD, Paul Abourjaily, PharmD, David Thaler, MD, PhD, Joseph Rencic, MD, FACP

Published in: Journal of General Internal Medicine | Issue 6/2015

Login to get access

Excerpt

A44-year-oldwoman with a history of cerebral palsy, intellectual disability, seizure disorder, and hypothyroidism was brought to the emergency department from her group home for increasing lethargy over the past day. At baseline she was bedbound, nonverbal, and did not follow commands. Her aide reported difficulty feeding her that morning. The patient’s family had recently noted abnormal twitching movements and occasional lateral neck movements to the right during eating, which were unlike her usual seizures. Review of systems was otherwise negative. In the emergency department, she was hypothermic (T 95.3°F) and hypotensive (BP 73/54 mmHg) with a heart rate of 80 beats/min. …
Literature
1.
go back to reference Woods NN. Science is fundamental: the role of biomedical knowledge in clinical reasoning. Med Educ. 2007;41:1173–7.CrossRefPubMed Woods NN. Science is fundamental: the role of biomedical knowledge in clinical reasoning. Med Educ. 2007;41:1173–7.CrossRefPubMed
2.
3.
go back to reference Mamede S, Schmidt HG, Rikers RM, Custers EJ, Splinter TA, van Saase JL. Conscious thought beats deliberation without attention in diagnostic decision-making: at least when you are an expert. Psychol Res. 2010;74:586–92.CrossRefPubMedCentralPubMed Mamede S, Schmidt HG, Rikers RM, Custers EJ, Splinter TA, van Saase JL. Conscious thought beats deliberation without attention in diagnostic decision-making: at least when you are an expert. Psychol Res. 2010;74:586–92.CrossRefPubMedCentralPubMed
4.
go back to reference Knudsen JF, Sokol GH, Flowers CM. Adjunctive topiramate enhances the risk of hypothermia associated with valproic acid therapy. J Clin Pharm Ther. 2008;33:513–9.CrossRefPubMed Knudsen JF, Sokol GH, Flowers CM. Adjunctive topiramate enhances the risk of hypothermia associated with valproic acid therapy. J Clin Pharm Ther. 2008;33:513–9.CrossRefPubMed
5.
go back to reference Zachariah SB, Zachariah A, Ananda R, Stewart JT. Hypothermia and thermoregulatory derangements induced by valproic acid. Neurology. 2000;55:150–1.CrossRefPubMed Zachariah SB, Zachariah A, Ananda R, Stewart JT. Hypothermia and thermoregulatory derangements induced by valproic acid. Neurology. 2000;55:150–1.CrossRefPubMed
6.
go back to reference Stout SC, Owens MJ, Lindsey KP, Knight DL, Nemeroff CB. Effects of sodium valproate on corticotropin-releasing factor systems in rat brain. Neuropsychopharmacology. 2001;24:624–31.CrossRefPubMed Stout SC, Owens MJ, Lindsey KP, Knight DL, Nemeroff CB. Effects of sodium valproate on corticotropin-releasing factor systems in rat brain. Neuropsychopharmacology. 2001;24:624–31.CrossRefPubMed
7.
go back to reference Gilmor ML, Skelton KH, Nemeroff CB, Owens MJ. The effects of chronic treatment with the mood stabilizers valproic acid and lithium on corticotropin-releasing factor neuronal systems. J Pharmacol Exp Ther. 2003;305:434–9.CrossRefPubMed Gilmor ML, Skelton KH, Nemeroff CB, Owens MJ. The effects of chronic treatment with the mood stabilizers valproic acid and lithium on corticotropin-releasing factor neuronal systems. J Pharmacol Exp Ther. 2003;305:434–9.CrossRefPubMed
8.
go back to reference Chalmers DT, Lovenberg TW, De Souza EB. Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J Neurosci. 1995;15:6340–50.PubMed Chalmers DT, Lovenberg TW, De Souza EB. Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J Neurosci. 1995;15:6340–50.PubMed
9.
go back to reference Wadzinski J, Franks R, Roane D, Bayard M. Valproate-associated hyperammonemic encephalopathy. J Am Board Fam Med. 2007;20:499–502.CrossRefPubMed Wadzinski J, Franks R, Roane D, Bayard M. Valproate-associated hyperammonemic encephalopathy. J Am Board Fam Med. 2007;20:499–502.CrossRefPubMed
10.
go back to reference Yamamoto Y, Takahashi Y, Suzuki E, et al. Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients. Epilepsy Res. 2012;101:202–9.CrossRefPubMed Yamamoto Y, Takahashi Y, Suzuki E, et al. Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients. Epilepsy Res. 2012;101:202–9.CrossRefPubMed
11.
go back to reference Warter JM, Marescaux C, Brandt C, et al. Sodium valproate associated with phenobarbital: effects on ammonia metabolism in humans. Epilepsia. 1983;24:628–33.CrossRefPubMed Warter JM, Marescaux C, Brandt C, et al. Sodium valproate associated with phenobarbital: effects on ammonia metabolism in humans. Epilepsia. 1983;24:628–33.CrossRefPubMed
12.
go back to reference Gomez-Ibanez A, Urrestarazu-Bolumburu E, Viteri-Torres C. Hyperammonemic encephalopathy related to valproate, phenobarbital, and topiramate synergism. Epilepsy Behav. 2011;21:480–2.CrossRefPubMed Gomez-Ibanez A, Urrestarazu-Bolumburu E, Viteri-Torres C. Hyperammonemic encephalopathy related to valproate, phenobarbital, and topiramate synergism. Epilepsy Behav. 2011;21:480–2.CrossRefPubMed
13.
go back to reference Mock CM, Schwetschenau KH. Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy. Am J Health Syst Pharm. 2012;69:35–9.CrossRefPubMed Mock CM, Schwetschenau KH. Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy. Am J Health Syst Pharm. 2012;69:35–9.CrossRefPubMed
Metadata
Title
Exercises In Clinical Reasoning
A Confusing Interaction
Authors
Urvi A. Shah, MD
Mark C. Henderson, MD
Paul Abourjaily, PharmD
David Thaler, MD, PhD
Joseph Rencic, MD, FACP
Publication date
01-06-2015
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 6/2015
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-014-3173-6

Other articles of this Issue 6/2015

Journal of General Internal Medicine 6/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.